Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.

Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.

Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.

Citing Articles

Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023-2024 Season in Andalusia, Spain (NIRSEGRAND).

Moreno-Perez D, Korobova A, Croche-Santander F, Cordon-Martinez A, Diaz-Morales O, Martinez-Campos L Vaccines (Basel). 2025; 13(2).

PMID: 40006722 PMC: 11861336. DOI: 10.3390/vaccines13020175.

Abu-Raya B, Langley J, Lavoie P CMAJ. 2024; 196(40):E1349-E1352.

PMID: 39586606 PMC: 11588394. DOI: 10.1503/cmaj.240780-f.

Nirsevimab to reduce infant morbidity from respiratory syncytial virus.

Abu-Raya B, Langley J, Lavoie P CMAJ. 2024; 196(32):E1114-E1117.

PMID: 39353638 PMC: 11444692. DOI: 10.1503/cmaj.240780.

References

Simoes E, Madhi S, Muller W, Atanasova V, Bosheva M, Cabanas F . Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of.... Lancet Child Adolesc Health. 2023; 7(3):180-189. PMC: 9940918. DOI: 10.1016/S2352-4642(22)00321-2. View

Munkstrup C, Lomholt F, Emborg H, Moller K, Krog J, Trebbien R . Early and intense epidemic of respiratory syncytial virus (RSV) in Denmark, August to December 2022. Euro Surveill. 2023; 28(1). PMC: 9817209. DOI: 10.2807/1560-7917.ES.2023.28.1.2200937. View

Broberg E, Nohynek H . Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention. Euro Surveill. 2023; 28(49). PMC: 10831406. DOI: 10.2807/1560-7917.ES.2023.28.49.2300686. View

Wilkins D, Yuan Y, Chang Y, Aksyuk A, Nunez B, Wahlby-Hamren U . Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023; 29(5):1172-1179. PMC: 10202809. DOI: 10.1038/s41591-023-02316-5. View

Mesle M, Sinnathamby M, Mook P, Pebody R, Lakhani A, Zambon M . Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022. Influenza Other Respir Viruses. 2023; 17(11):e13219. PMC: 10661829. DOI: 10.1111/irv.13219. View

Lopez-Lacort M, Munoz-Quiles C, Mira-Iglesias A, Lopez-Labrador F, Mengual-Chulia B, Fernandez-Garcia C . Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024; 29(6). PMC: 10853977. DOI: 10.2807/1560-7917.ES.2024.29.6.2400046. View

Gea-Izquierdo E, Gil-Prieto R, Hernandez-Barrera V, Gil-de-Miguel A . Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021. Hum Vaccin Immunother. 2023; 19(2):2231818. PMC: 10348019. DOI: 10.1080/21645515.2023.2231818. View

Ang H, Menegale F, Preziosi G, Pariani E, Migliari M, Pellegrinelli L . Reconstructing the impact of COVID-19 on the immunity gap and transmission of respiratory syncytial virus in Lombardy, Italy. EBioMedicine. 2023; 95:104745. PMC: 10432612. DOI: 10.1016/j.ebiom.2023.104745. View

Muller W, Madhi S, Nunez B, Baca Cots M, Bosheva M, Dagan R . Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023; 388(16):1533-1534. DOI: 10.1056/NEJMc2214773. View

10.

Wildenbeest J, Billard M, Zuurbier R, Korsten K, Langedijk A, van de Ven P . The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2022; 11(4):341-353. PMC: 9764871. DOI: 10.1016/S2213-2600(22)00414-3. View

11.

Goldstein E, Cobey S, Takahashi S, Miller J, Lipsitch M . Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. PLoS Med. 2011; 8(7):e1001051. PMC: 3130020. DOI: 10.1371/journal.pmed.1001051. View

12.

Martinon-Torres F, Miras-Carballal S, Duran-Parrondo C . Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023; 28(49). PMC: 10831408. DOI: 10.2807/1560-7917.ES.2023.28.49.2300606. View

13.

Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C . Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024; 29(4). PMC: 10986653. DOI: 10.2807/1560-7917.ES.2024.29.4.2400033. View